{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T00:09:05Z","timestamp":1784938145294,"version":"3.55.0"},"reference-count":125,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP25bm1123074"],"award-info":[{"award-number":["JP25bm1123074"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP256f0137009"],"award-info":[{"award-number":["JP256f0137009"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["23H02936"],"award-info":[{"award-number":["23H02936"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["24K22136"],"award-info":[{"award-number":["24K22136"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["23K15303"],"award-info":[{"award-number":["23K15303"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["25K19580"],"award-info":[{"award-number":["25K19580"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007449","name":"Takeda Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007449","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100024224","name":"Chemo-Sero-Therapeutic Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100024224","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019356","name":"SGH Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019356","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004091","name":"Kumamoto University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004091","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Viruses induce approximately 12% of human cancers, including lymphomas. In the case of T\/NK cell neoplasms, human T-cell leukemia virus type I (HTLV-1) causes adult T-cell leukemia-lymphoma (ATL), and Epstein-Barr virus (EBV) is associated with extranodal NK\/T-cell lymphoma (ENKTCL) and chronic active Epstein\u2013Barr virus disease (CAEBV). Common mechanisms for lymphoma development have been proposed. Viral genes, such as\n                    <jats:italic>tax<\/jats:italic>\n                    and\n                    <jats:italic>HTLV-1 bZIP factor (HBZ)<\/jats:italic>\n                    of HTLV-1, and\n                    <jats:italic>latent membrane protein 1 (LMP1)<\/jats:italic>\n                    and\n                    <jats:italic>BamHI A rightward transcript microRNA (miRNA-BART)<\/jats:italic>\n                    of EBV, contribute to host immune evasion and modulation of host signaling pathways, resulting in the persistence of viral-infected cells. This viral strategy is closely associated with oncogenesis. Furthermore, the long-term survival of infected cells leads to the accumulation of somatic mutations and aberrant epigenetic alterations. These events eventually lead to ATL, ENKTCL, and the lymphoma-like subset of CAEBV. Interrupting these common oncogenic mechanisms is a promising therapeutic strategy for viral-driven lymphomas with poor prognoses.\n                  <\/jats:p>","DOI":"10.1007\/s12185-025-04156-0","type":"journal-article","created":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T10:29:40Z","timestamp":1767781780000},"page":"476-486","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Viral-driven oncogenesis in T\/NK-cell lymphomas: parallels and divergences between HTLV-1 and EBV"],"prefix":"10.1007","volume":"123","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1272-3738","authenticated-orcid":false,"given":"Takafumi","family":"Shichijo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-ichirou","family":"Yasunaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,7]]},"reference":[{"key":"4156_CR1","doi-asserted-by":"publisher","first-page":"26","DOI":"10.35772\/ghm.2021.01037","volume":"4","author":"M Inoue","year":"2022","unstructured":"Inoue M, Hirabayashi M, Abe SK, Katanoda K, Sawada N, Lin Y, et al. Burden of cancer attributable to modifiable factors in Japan in 2015. Glob Health Med. 2022;4:26\u201336.","journal-title":"Glob Health Med"},{"issue":"3","key":"4156_CR2","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.chom.2014.02.011","volume":"15","author":"EA Mesri","year":"2014","unstructured":"Mesri EA, Feitelson MA, Munger K. Human viral oncogenesis: a cancer hallmarks analysis. Cell Host Microbe. 2014;15(3):266\u201382. https:\/\/doi.org\/10.1016\/j.chom.2014.02.011.","journal-title":"Cell Host Microbe"},{"issue":"11","key":"4156_CR3","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1038\/s41579-018-0064-6","volume":"16","author":"NA Krump","year":"2018","unstructured":"Krump NA, You J. Molecular mechanisms of viral oncogenesis in humans. Nat Rev Microbiol. 2018;16(11):684\u201398. https:\/\/doi.org\/10.1038\/s41579-018-0064-6.","journal-title":"Nat Rev Microbiol"},{"issue":"1","key":"4156_CR4","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/s41392-025-02197-9","volume":"10","author":"Q Xiao","year":"2025","unstructured":"Xiao Q, Liu Y, Li T, Wang C, He S, Zhai L, et al. Viral oncogenesis in cancer: from mechanisms to therapeutics. Signal Transduct Target Ther. 2025;10(1):151.","journal-title":"Signal Transduct Target Ther"},{"key":"4156_CR5","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/nrc2111","volume":"7","author":"M Matsuoka","year":"2007","unstructured":"Matsuoka M, Jeang K. T: Human T-cell leukaemia virus type 1 (HTLV-1) infectivity and cellular transformation. Nat Rev Cancer. 2007;7:270\u201380.","journal-title":"Nat Rev Cancer"},{"issue":"10","key":"4156_CR6","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1038\/nrc1452","volume":"4","author":"LS Young","year":"2004","unstructured":"Young LS, Rickinson AB. Epstein-Barr virus: 40 years on. Nat Rev Cancer. 2004;4(10):757\u201368.","journal-title":"Nat Rev Cancer"},{"key":"4156_CR7","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1146\/annurev-pathol-012513-104656","volume":"9","author":"E Cesarman","year":"2014","unstructured":"Cesarman E. Gammaherpesviruses and lymphoproliferative disorders. Annu Rev Pathol. 2014;9:349\u201372.","journal-title":"Annu Rev Pathol"},{"key":"4156_CR8","doi-asserted-by":"publisher","first-page":"7415","DOI":"10.1073\/pnas.77.12.7415","volume":"77","author":"BJ Poiesz","year":"1980","unstructured":"Poiesz BJ, Ruscetti FW, Gazdar AF, Bunn PA, Minna JD, Gallo RC. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci USA. 1980;77:7415\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"key":"4156_CR9","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1073\/pnas.79.6.2031","volume":"79","author":"M Yoshida","year":"1982","unstructured":"Yoshida M, Miyoshi I, Hinuma Y. Isolation and characterization of retrovirus from cell lines of human adult T-cell leukemia and its implication in the disease. Proc Natl Acad Sci USA. 1982;79:2031\u20135.","journal-title":"Proc Natl Acad Sci USA"},{"key":"4156_CR10","doi-asserted-by":"publisher","first-page":"6476","DOI":"10.1073\/pnas.78.10.6476","volume":"78","author":"Y Hinuma","year":"1981","unstructured":"Hinuma Y, Nagata K, Hanaoka M, Nakai M, Matsumoto T, Kinoshita KI, et al. Adult T-cell leukemia: antigen in an ATL cell line and detection of antibodies to the antigen in human sera. Proc Natl Acad Sci USA. 1981;78:6476\u201380.","journal-title":"Proc Natl Acad Sci USA"},{"key":"4156_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2012.00388","volume":"3","author":"A Gessain","year":"2012","unstructured":"Gessain A, Cassar O. Epidemiological aspects and world distribution of HTLV-1 infection. Front Microbiol. 2012;3:388.","journal-title":"Front Microbiol"},{"key":"4156_CR12","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1182\/blood.V50.3.481.481","volume":"50","author":"T Uchiyama","year":"1977","unstructured":"Uchiyama T, Yodoi H, Sagawa K, Takatsuki K, Uchino H. Adult T-cell leukemia: clinical and hematologic features of 16 cases. Blood. 1977;50:481\u201392.","journal-title":"Blood"},{"key":"4156_CR13","doi-asserted-by":"publisher","first-page":"e517","DOI":"10.1016\/S1470-2045(14)70202-5","volume":"15","author":"K Ishitsuka","year":"2014","unstructured":"Ishitsuka K, Tamura K. Human T-cell leukaemia virus type I and adult T-cell leukaemia-lymphoma. Lancet Oncol. 2014;15:e517\u201326.","journal-title":"Lancet Oncol"},{"key":"4156_CR14","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1182\/blood-2016-09-692574","volume":"129","author":"T Watanabe","year":"2017","unstructured":"Watanabe T. Adult T-cell leukemia: molecular basis for clonal expansion and transformation of HTLV-1\u2013infected T cells. Blood. 2017;129:1071\u201381.","journal-title":"Blood"},{"key":"4156_CR15","first-page":"2299","volume":"141","author":"CRM Bangham","year":"2023","unstructured":"Bangham CRM. HTLV-1 persistence and the oncogenesis of adult T cell leukemia\/lymphoma. Blood. 2023;141:2299\u2013306.","journal-title":"Blood"},{"key":"4156_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.coviro.2025.101480","volume":"73","author":"T Shichijo","year":"2025","unstructured":"Shichijo T, Yasunaga JI. Human T-cell leukemia virus type I: modulation of viral gene expression and perturbation of host signaling pathways lead to persistent infection. Curr Opin Virol. 2025;73:101480. https:\/\/doi.org\/10.1016\/j.coviro.2025.101480.","journal-title":"Curr Opin Virol"},{"key":"4156_CR17","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1182\/blood-2015-03-632489","volume":"126","author":"H Katsuya","year":"2015","unstructured":"Katsuya H, Ishitsuka K, Utsunomiya A, Hanada S, Eto T, Moriuchi Y, et al. Treatment and survival among 1594 patients with ATL. Blood. 2015;126:2570\u20137.","journal-title":"Blood"},{"key":"4156_CR18","doi-asserted-by":"publisher","first-page":"4567","DOI":"10.1111\/cas.14658","volume":"111","author":"Y Imaizumi","year":"2020","unstructured":"Imaizumi Y, Iwanaga M, Nosaka K, Ishitsuka K, Ishizawa K, Ito S, et al. Prognosis of patients with adult T-cell leukemia\/lymphoma in Japan: a nationwide hospital-based study. Cancer Sci. 2020;111:4567\u201380.","journal-title":"Cancer Sci"},{"key":"4156_CR19","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1200\/JCO.18.00501","volume":"37","author":"LB Cook","year":"2019","unstructured":"Cook LB, Fuji S, Hermine O, Bazarbachi A, Ramos JC, Ratner L, et al. Revised adult T-cell leukemia-lymphoma international consensus meeting report. J Clin Oncol. 2019;37:677\u201387. https:\/\/doi.org\/10.1200\/JCO.18.00501.","journal-title":"J Clin Oncol"},{"key":"4156_CR20","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1182\/blood.2019004045","volume":"137","author":"LB Cook","year":"2021","unstructured":"Cook LB, Phillips A. A: How I treat adult T-cell leukemia\/lymphoma. Blood. 2021;137:459\u201370.","journal-title":"Blood"},{"issue":"12","key":"4156_CR21","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1182\/blood.2024027902","volume":"146","author":"M Yoshimitsu","year":"2025","unstructured":"Yoshimitsu M, Choi I, Kusumoto S, Shimokawa M, Utsunomiya A, Suehiro Y, et al. A phase 2 trial of CHOP with anti-CCR4 antibody mogamulizumab for older patients with adult T-cell leukemia\/lymphoma. Blood. 2025;146(12):1440\u20139. https:\/\/doi.org\/10.1182\/blood.2024027902.","journal-title":"Blood"},{"key":"4156_CR22","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1111\/bjh.18281","volume":"198","author":"T Shichijo","year":"2022","unstructured":"Shichijo T, Nosaka K, Tatetsu H, Higuchi Y, Endo S, Inoue Y, et al. Beneficial impact of first-line mogamulizumab-containing chemotherapy in adult T-cell leukaemia-lymphoma. Br J Haematol. 2022;198:983\u20137. https:\/\/doi.org\/10.1111\/bjh.18281.","journal-title":"Br J Haematol"},{"issue":"10","key":"4156_CR23","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1182\/blood.2022016862","volume":"141","author":"K Izutsu","year":"2023","unstructured":"Izutsu K, Makita S, Nosaka K, Yoshimitsu M, Utsunomiya A, Kusumoto S, et al. An open-label, single-arm phase 2 trial of valemetostat for relapsed or refractory adult T-cell leukemia\/lymphoma. Blood. 2023;141(10):1159\u201368.","journal-title":"Blood"},{"key":"4156_CR24","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.70219","author":"T Shichijo","year":"2025","unstructured":"Shichijo T, Tatetsu H, Higuchi Y, Miyakawa T, Nosaka K, Nakamura T, et al. Prognostic impact of valemetostat in relapsed\/refractory adult T-cell leukaemia-lymphoma. Br J Haematol. 2025. https:\/\/doi.org\/10.1111\/bjh.70219.","journal-title":"Br J Haematol"},{"key":"4156_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2025.107680","volume":"152","author":"T Shichijo","year":"2025","unstructured":"Shichijo T, Yasunaga JI. Stratagems of HTLV-1 for persistent infection and the resultant oncogenesis: immune evasion and clonal expansion. Leuk Res. 2025;152:107680. https:\/\/doi.org\/10.1016\/j.leukres.2025.107680.","journal-title":"Leuk Res"},{"key":"4156_CR26","doi-asserted-by":"publisher","first-page":"5952","DOI":"10.1038\/sj.onc.1208969","volume":"24","author":"SC Sun","year":"2005","unstructured":"Sun SC, Yamaoka S. Activation of NF-\u03baB by HTLV-I and implications for cell transformation. Oncogene. 2005;24:5952\u201364.","journal-title":"Oncogene"},{"key":"4156_CR27","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2115316119","volume":"119","author":"T Zhao","year":"2022","unstructured":"Zhao T, Wang Z, Fang J, Cheng W, Zhang Y, Huang J, et al. HTLV-1 activates YAP via NF-kappaB\/p65 to promote oncogenesis. Proc Natl Acad Sci USA. 2022;119:e2115316119. https:\/\/doi.org\/10.1073\/pnas.2115316119.","journal-title":"Proc Natl Acad Sci USA"},{"key":"4156_CR28","doi-asserted-by":"publisher","first-page":"4856","DOI":"10.1128\/JVI.73.6.4856-4865.1999","volume":"73","author":"MD Robek","year":"1999","unstructured":"Robek MD, Ratner L. Immortalization of CD4+ and CD8+ T lymphocytes by human T-cell leukemia virus type 1 tax mutants expressed in a functional molecular clone. J Virol. 1999;73:4856\u201365.","journal-title":"J Virol"},{"key":"4156_CR29","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1111\/j.1365-2443.2006.00927.x","volume":"11","author":"K Okamoto","year":"2006","unstructured":"Okamoto K, Fujisawa J, Reth M, Yonehara S. Human T-cell leukemia virus type-I oncoprotein Tax inhibits Fas-mediated apoptosis by inducing cellular FLIP through activation of NF-kappaB. Genes Cells. 2006;11:177\u201391.","journal-title":"Genes Cells"},{"key":"4156_CR30","doi-asserted-by":"publisher","first-page":"E1269","DOI":"10.1073\/pnas.1715724115","volume":"115","author":"M Mahgoub","year":"2018","unstructured":"Mahgoub M, Yasunaga JI, Iwami S, Nakaoka S, Koizumi Y, Shimura K, et al. Sporadic on\/off switching of HTLV-1 Tax expression is crucial to maintain the whole population of virus-induced leukemic cells. Proc Natl Acad Sci USA. 2018;115:E1269\u201378. https:\/\/doi.org\/10.1073\/pnas.1715724115.","journal-title":"Proc Natl Acad Sci USA"},{"key":"4156_CR31","doi-asserted-by":"publisher","first-page":"5380","DOI":"10.1038\/s41467-024-49737-5","volume":"15","author":"S Mohanty","year":"2024","unstructured":"Mohanty S, Suklabaidya S, Lavorgna A, Ueno T, Fujisawa JI, Ngouth N, et al. The tyrosine kinase KDR is essential for the survival of HTLV-1-infected T cells by stabilizing the Tax oncoprotein. Nat Commun. 2024;15:5380. https:\/\/doi.org\/10.1038\/s41467-024-49737-5.","journal-title":"Nat Commun"},{"key":"4156_CR32","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1182\/blood-2010-12-326199","volume":"118","author":"T Zhao","year":"2011","unstructured":"Zhao T, Satou Y, Sugata K, Miyazato P, Green PL, Imamura T, et al. HTLV-1 bZIP factor enhances TGF-beta signaling through p300 coactivator. Blood. 2011;118:1865\u201376. https:\/\/doi.org\/10.1182\/blood-2010-12-326199.","journal-title":"Blood"},{"key":"4156_CR33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1001274","volume":"7","author":"Y Satou","year":"2011","unstructured":"Satou Y, Yasunaga J, Zhao T, Yoshida M, Miyazato P, Takai K, et al. HTLV-1 bZIP factor induces T-cell lymphoma and systemic inflammation in vivo. PLoS Pathog. 2011;7:e1001274. https:\/\/doi.org\/10.1371\/journal.ppat.1001274.","journal-title":"PLoS Pathog"},{"key":"4156_CR34","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1003630","volume":"9","author":"N Yamamoto-Taguchi","year":"2013","unstructured":"Yamamoto-Taguchi N, Satou Y, Miyazato P, Ohshima K, Nakagawa M, Katagiri K, et al. HTLV-1 bZIP factor induces inflammation through labile Foxp3 expression. PLoS Pathog. 2013;9:e1003630. https:\/\/doi.org\/10.1371\/journal.ppat.1003630.","journal-title":"PLoS Pathog"},{"key":"4156_CR35","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1005120","volume":"11","author":"Y Mitagami","year":"2015","unstructured":"Mitagami Y, Yasunaga J, Kinosada H, Ohshima K, Matsuoka M. Interferon-gamma promotes inflammation and development of T-cell lymphoma in HTLV-1 bZIP factor transgenic mice. PLoS Pathog. 2015;11:e1005120. https:\/\/doi.org\/10.1371\/journal.ppat.1005120.","journal-title":"PLoS Pathog"},{"key":"4156_CR36","doi-asserted-by":"publisher","first-page":"5068","DOI":"10.1158\/0008-5472.CAN-16-0361","volume":"76","author":"K Sugata","year":"2016","unstructured":"Sugata K, Yasunaga J, Kinosada H, Mitobe Y, Furuta R, Mahgoub M, et al. HTLV-1 viral factor HBZ induces CCR4 to promote T-cell migration and proliferation. Cancer Res. 2016;76:5068\u201379. https:\/\/doi.org\/10.1158\/0008-5472.CAN-16-0361.","journal-title":"Cancer Res"},{"key":"4156_CR37","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1005372","volume":"12","author":"K Yasuma","year":"2016","unstructured":"Yasuma K, Yasunaga J, Takemoto K, Sugata K, Mitobe Y, Takenouchi N, et al. HTLV-1 bZIP factor impairs anti-viral immunity by inducing co-inhibitory molecule, T cell immunoglobulin and ITIM domain (TIGIT). PLoS Pathog. 2016;12:e1005372. https:\/\/doi.org\/10.1371\/journal.ppat.1005372.","journal-title":"PLoS Pathog"},{"key":"4156_CR38","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1006597","author":"L Sawada","year":"2017","unstructured":"Sawada L, Nagano Y, Hasegawa A, Kanai H, Nogami K, Ito S, et al. IL-10-mediated signals act as a switch for lymphoproliferation in human T-cell leukemia virus type-1 infection by activating the STAT3 and IRF4 pathways. PLoS Pathog. 2017. https:\/\/doi.org\/10.1371\/journal.ppat.1006597.","journal-title":"PLoS Pathog"},{"key":"4156_CR39","doi-asserted-by":"publisher","first-page":"13740","DOI":"10.1073\/pnas.1922884117","volume":"117","author":"Y Higuchi","year":"2020","unstructured":"Higuchi Y, Yasunaga JI, Mitagami Y, Tsukamoto H, Nakashima K, Ohshima K, et al. HTLV-1 induces T cell malignancy and inflammation by viral antisense factor-mediated modulation of the cytokine signaling. Proc Natl Acad Sci USA. 2020;117:13740\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"key":"4156_CR40","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2309925121","volume":"121","author":"T Shichijo","year":"2024","unstructured":"Shichijo T, Yasunaga JI, Sato K, Nosaka K, Toyoda K, Watanabe M, et al. Vulnerability to APOBEC3G linked to the pathogenicity of deltaretroviruses. Proc Natl Acad Sci USA. 2024;121:e2309925121. https:\/\/doi.org\/10.1073\/pnas.2309925121.","journal-title":"Proc Natl Acad Sci USA"},{"key":"4156_CR41","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1013158","volume":"21","author":"O Hussein","year":"2025","unstructured":"Hussein O, Mahgoub M, Shichijo T, Nakagawa S, Tanabe J, Akari H, et al. Evolution of primate T-cell leukemia virus type 1 accessory genes and functional divergence of its antisense proteins. PLoS Pathog. 2025;21:e1013158. https:\/\/doi.org\/10.1371\/journal.ppat.1013158.","journal-title":"PLoS Pathog"},{"key":"4156_CR42","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2420756122","volume":"122","author":"W Zhang","year":"2025","unstructured":"Zhang W, Shichijo T, Chen X, Watanabe M, Nosaka K, Matsuoka M, et al. JunB-HBZ nuclear translocation by TGF-\u03b2 is a key driver in HTLV-1-mediated leukemogenesis. Proc Natl Acad Sci USA. 2025;122:e2420756122. https:\/\/doi.org\/10.1073\/pnas.2420756122.","journal-title":"Proc Natl Acad Sci USA"},{"key":"4156_CR43","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2014783118","volume":"118","author":"G Ma","year":"2021","unstructured":"Ma G, Yasunaga JI, Shimura K, Takemoto K, Watanabe M, Amano M, et al. Human retroviral antisense mRNAs are retained in the nuclei of infected cells for viral persistence. Proc Natl Acad Sci USA. 2021;118:e2014783118. https:\/\/doi.org\/10.1073\/pnas.2014783118.","journal-title":"Proc Natl Acad Sci USA"},{"key":"4156_CR44","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.ccell.2018.06.014","volume":"34","author":"M Nakagawa","year":"2018","unstructured":"Nakagawa M, Shaffer AL 3rd, Ceribelli M, Zhang M, Wright G, Huang DW, et al. Targeting the HTLV-I-regulated BATF3\/IRF4 transcriptional network in adult T cell leukemia\/lymphoma. Cancer Cell. 2018;34:286-297.e10. https:\/\/doi.org\/10.1016\/j.ccell.2018.06.014.","journal-title":"Cancer Cell"},{"key":"4156_CR45","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1158\/0008-5472.CAN-13-0436","volume":"74","author":"A Tanaka-Nakanishi","year":"2014","unstructured":"Tanaka-Nakanishi A, Yasunaga J-i, Takai K, Matsuoka M. HTLV-1 bZIP factor suppresses apoptosis by attenuating the function of FoxO3a and altering its localization. Cancer Res. 2014;74:188\u2013200. https:\/\/doi.org\/10.1158\/0008-5472.CAN-13-0436.","journal-title":"Cancer Res"},{"key":"4156_CR46","doi-asserted-by":"publisher","first-page":"4143","DOI":"10.1158\/0008-5472.CAN-15-0942","volume":"75","author":"Y Mitobe","year":"2015","unstructured":"Mitobe Y, Yasunaga J-i, Furuta R, Matsuoka M. HTLV-1 bZIP factor RNA and protein impart distinct functions on T-cell proliferation and survival. Cancer Res. 2015;75:4143\u201352. https:\/\/doi.org\/10.1158\/0008-5472.CAN-15-0942.","journal-title":"Cancer Res"},{"key":"4156_CR47","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1158\/2643-3230.BCD-22-0139","volume":"4","author":"K Toyoda","year":"2023","unstructured":"Toyoda K, Yasunaga JI, Shichijo T, Arima Y, Tsujita K, Tanaka A, et al. HTLV-1 bZIP factor-induced reprogramming of lactate metabolism and epigenetic status promote leukemic cell expansion. Blood Cancer Discov. 2023;4:374\u201393. https:\/\/doi.org\/10.1158\/2643-3230.BCD-22-0139.","journal-title":"Blood Cancer Discov"},{"key":"4156_CR48","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2416412122","volume":"122","author":"B Liu","year":"2025","unstructured":"Liu B, Yasunaga JI, Liang Y, Zhou R, Yang S, Yuan X, et al. Identification of AK4 and RHOC as potential oncogenes addicted by adult T cell leukemia. Proc Natl Acad Sci USA. 2025;122:e2416412122. https:\/\/doi.org\/10.1073\/pnas.2416412122.","journal-title":"Proc Natl Acad Sci USA"},{"key":"4156_CR49","doi-asserted-by":"publisher","first-page":"3065","DOI":"10.1182\/blood.V88.8.3065.bloodjournal8883065","volume":"88","author":"S Tamiya","year":"1996","unstructured":"Tamiya S, Matsuoka M, Etoh K, Watanabe T, Kamihira S, Yamaguchi K, et al. Two types of defective human T-lymphotropic virus type I provirus in adult T-cell leukemia. Blood. 1996;88:3065\u201373.","journal-title":"Blood"},{"key":"4156_CR50","doi-asserted-by":"publisher","first-page":"5714","DOI":"10.1128\/JVI.02511-06","volume":"81","author":"M Miyazaki","year":"2007","unstructured":"Miyazaki M, Yasunaga J, Taniguchi Y, Tamiya S, Nakahata T, Matsuoka M. Preferential selection of human T-cell leukemia virus type 1 provirus lacking the 5\u2019 long terminal repeat during oncogenesis. J Virol. 2007;81:5714\u201323. https:\/\/doi.org\/10.1128\/JVI.02511-06.","journal-title":"J Virol"},{"key":"4156_CR51","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/j.celrep.2019.09.016","volume":"29","author":"H Katsuya","year":"2019","unstructured":"Katsuya H, Islam S, Tan BJY, Ito J, Miyazato P, Matsuo M, et al. The nature of the HTLV-1 provirus in naturally infected individuals analyzed by the viral DNA-capture-seq approach. Cell Rep. 2019;29:724-735.e4. https:\/\/doi.org\/10.1016\/j.celrep.2019.09.016.","journal-title":"Cell Rep"},{"key":"4156_CR52","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1002\/ijc.20007","volume":"109","author":"S Takeda","year":"2004","unstructured":"Takeda S, Maeda M, Morikawa S, Taniguchi Y, Yasunaga J, Nosaka K, et al. Genetic and epigenetic inactivation of tax gene in adult T\u2010cell leukemia cells. Int J Cancer. 2004;109:559\u201367. https:\/\/doi.org\/10.1002\/ijc.20007.","journal-title":"Int J Cancer"},{"key":"4156_CR53","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/1742-4690-2-64","volume":"2","author":"Y Taniguchi","year":"2005","unstructured":"Taniguchi Y, Nosaka K, Yasunaga J, Maeda M, Mueller N, Okayama A, et al. Silencing of human T-cell leukemia virus type I gene transcription by epigenetic mechanisms. Retrovirology. 2005;2:64. https:\/\/doi.org\/10.1186\/1742-4690-2-64.","journal-title":"Retrovirology"},{"key":"4156_CR54","doi-asserted-by":"publisher","first-page":"7278","DOI":"10.1128\/JVI.02239-09","volume":"84","author":"J Fan","year":"2010","unstructured":"Fan J, Ma G, Nosaka K, Tanabe J, Satou Y, Koito A, et al. APOBEC3G generates nonsense mutations in human T-cell leukemia virus type 1 proviral genomes in vivo. J Virol. 2010;84:7278\u201387. https:\/\/doi.org\/10.1128\/JVI.02239-09.","journal-title":"J Virol"},{"key":"4156_CR55","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1073\/pnas.0507631103","volume":"103","author":"Y Satou","year":"2006","unstructured":"Satou Y, Yasunaga J-i, Yoshida M, Matsuoka M. HTLV-I basic leucine zipper factor gene mRNA supports proliferation of adult T cell leukemia cells. Proc Natl Acad Sci USA. 2006;103:720\u20135. https:\/\/doi.org\/10.1073\/pnas.0507631103.","journal-title":"Proc Natl Acad Sci USA"},{"key":"4156_CR56","doi-asserted-by":"publisher","first-page":"9359","DOI":"10.1128\/JVI.00242-08","volume":"82","author":"M Yoshida","year":"2008","unstructured":"Yoshida M, Satou Y, Yasunaga J-i, Fujisawa J, Matsuoka M. Transcriptional control of spliced and unspliced human T-cell leukemia virus type 1 bZIP factor (HBZ) gene. J Virol. 2008;82:9359\u201368. https:\/\/doi.org\/10.1128\/JVI.00242-08.","journal-title":"J Virol"},{"key":"4156_CR57","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1038\/s41564-025-02006-7","volume":"10","author":"K Sugata","year":"2025","unstructured":"Sugata K, Rahman A, Niimura K, Monde K, Ueno T, Rajib SA, et al. Intragenic viral silencer element regulates HTLV-1 latency via RUNX complex recruitment. Nat Microbiol. 2025;10:1447\u201362. https:\/\/doi.org\/10.1038\/s41564-025-02006-7.","journal-title":"Nat Microbiol"},{"key":"4156_CR58","doi-asserted-by":"publisher","unstructured":"Sonoda M, Tanaka A, Kiik H, Ramanayake S, Nosaka K, Takenouchi N, et al. Intra-pol proviral open region of HTLV-1 controls the transcription from both long terminal repeats. PREPRINT (Version 1) available at Research Square. 2025. https:\/\/doi.org\/10.21203\/rs.3.rs-6815109\/v1.","DOI":"10.21203\/rs.3.rs-6815109\/v1"},{"key":"4156_CR59","doi-asserted-by":"publisher","first-page":"3054","DOI":"10.1073\/pnas.1423199113","volume":"113","author":"Y Satou","year":"2016","unstructured":"Satou Y, Miyazato P, Ishihara K, Yaguchi H, Melamed A, Miura M, et al. The retrovirus HTLV-1 inserts an ectopic CTCF-binding site into the human genome. Proc Natl Acad Sci USA. 2016;113:3054\u20139. https:\/\/doi.org\/10.1073\/pnas.1423199113.","journal-title":"Proc Natl Acad Sci USA"},{"key":"4156_CR60","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1038\/s41467-022-30029-9","volume":"13","author":"M Matsuo","year":"2022","unstructured":"Matsuo M, Ueno T, Monde K, Sugata K, Tan BJY, Rahman A, et al. Identification and characterization of a novel enhancer in the HTLV-1 proviral genome. Nat Commun. 2022;13:2405. https:\/\/doi.org\/10.1038\/s41467-022-30029-9.","journal-title":"Nat Commun"},{"key":"4156_CR61","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1182\/blood.2019002665","volume":"135","author":"AG Rowan","year":"2020","unstructured":"Rowan AG, Dillon R, Witkover A, Melamed A, Demontis MA, Gillet NA, et al. Evolution of retrovirus-infected premalignant T-cell clones prior to adult T-cell leukemia\/lymphoma diagnosis. Blood. 2020;135:2023\u201332.","journal-title":"Blood"},{"key":"4156_CR62","first-page":"4862","volume":"57","author":"K Etoh","year":"1997","unstructured":"Etoh K, Tamiya S, Yamaguchi K, Okayama A, Tsubouchi H, Ideta T, et al. Persistent clonal proliferation of human T-lymphotropic virus type I-infected cells in vivo. Cancer Res. 1997;57:4862\u20137.","journal-title":"Cancer Res"},{"key":"4156_CR63","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1038\/ng.3415","volume":"47","author":"K Kataoka","year":"2015","unstructured":"Kataoka K, Nagata Y, Kitanaka A, Shiraishi Y, Shimamura T, Yasunaga J, et al. Integrated molecular analysis of adult T cell leukemia\/lymphoma. Nat Genet. 2015;47:1304\u201315.","journal-title":"Nat Genet"},{"key":"4156_CR64","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1182\/blood.2021013568","volume":"139","author":"Y Kogure","year":"2022","unstructured":"Kogure Y, Kameda T, Koya J, Yoshimitsu M, Nosaka K, Yasunaga JI, et al. Whole-genome landscape of adult T-cell leukemia\/lymphoma. Blood. 2022;139:967\u201382.","journal-title":"Blood"},{"key":"4156_CR65","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1007\/s12185-023-03547-5","volume":"117","author":"J-i Yasunaga","year":"2023","unstructured":"Yasunaga J-i. Viral, genetic, and immune factors in the oncogenesis of adult T-cell leukemia\/lymphoma. Int J Hematol. 2023;117:504\u201311.","journal-title":"Int J Hematol"},{"key":"4156_CR66","doi-asserted-by":"publisher","first-page":"4509","DOI":"10.1038\/onc.2015.510","volume":"35","author":"A Kawatsuki","year":"2016","unstructured":"Kawatsuki A, Yasunaga J-i, Mitobe Y, Green PL, Matsuoka M. HTLV-1 bZIP factor protein targets the Rb\/E2F-1 pathway to promote proliferation and apoptosis of primary CD4+ T cells. Oncogene. 2016;35:4509\u201317.","journal-title":"Oncogene"},{"key":"4156_CR67","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.18632\/oncotarget.6424","volume":"7","author":"DG Wright","year":"2016","unstructured":"Wright DG, Marchal C, Hoang K, Ankney JA, Nguyen ST, Rushing AW, et al. Human T-cell leukemia virus type-1-encoded protein HBZ represses p53 function by inhibiting the acetyltransferase activity of p300\/CBP and HBO1. Oncotarget. 2016;7:1687\u2013706.","journal-title":"Oncotarget"},{"key":"4156_CR68","doi-asserted-by":"publisher","first-page":"23903","DOI":"10.1074\/jbc.M803116200","volume":"283","author":"I Clerc","year":"2008","unstructured":"Clerc I, Polakowski N, Andr\u00e9-Arpin C, Cook P, Barbeau B, Mesnard JM, et al. An interaction between the human T cell leukemia virus type 1 basic leucine zipper factor (HBZ) and the KIX domain of p300\/CBP contributes to the down-regulation of Tax-dependent viral transcription by HBZ. J Biol Chem. 2008;283:23903\u201313.","journal-title":"J Biol Chem"},{"issue":"7607","key":"4156_CR69","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/nature18294","volume":"534","author":"K Kataoka","year":"2016","unstructured":"Kataoka K, Shiraishi Y, Takeda Y, Sakata S, Matsumoto M, Nagano S, et al. Aberrant PD-L1 expression through 3\u2019-UTR disruption in multiple cancers. Nature. 2016;534(7607):402\u20136. https:\/\/doi.org\/10.1038\/nature18294.","journal-title":"Nature"},{"key":"4156_CR70","doi-asserted-by":"publisher","first-page":"4821","DOI":"10.1038\/s41467-021-25101-9","volume":"12","author":"M Yamagishi","year":"2021","unstructured":"Yamagishi M, Kubokawa M, Kuze Y, Suzuki A, Yokomizo A, Kobayashi S, et al. Chronological genome and single-cell transcriptome integration characterizes the evolutionary process of adult T cell leukemia-lymphoma. Nat Commun. 2021;12:4821. https:\/\/doi.org\/10.1038\/s41467-021-25101-9.","journal-title":"Nat Commun"},{"key":"4156_CR71","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00458-8","author":"SN Wolf","year":"2021","unstructured":"Wolf SN, Haddow J, Greiller C, Taylor GP, Cook LBM, Rowan AG. Quantification of T cell clonality in human T cell leukaemia virus type-1 carriers can detect the development of adult T cell leukaemia early. Blood Cancer J. 2021. https:\/\/doi.org\/10.1038\/s41408-021-00458-8.","journal-title":"Blood Cancer J"},{"key":"4156_CR72","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1111\/cas.15997","volume":"115","author":"A Yamada","year":"2024","unstructured":"Yamada A, Yasunaga JI, Liang L, Zhang W, Sunagawa J, Nakaoka S, et al. Anti\u2010HTLV\u20101 immunity combined with proviral load as predictive biomarkers for adult T\u2010cell leukemia\u2010lymphoma. Cancer Sci. 2024;115:310\u201320.","journal-title":"Cancer Sci"},{"key":"4156_CR73","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1182\/blood-2009-12-257410","volume":"116","author":"M Iwanaga","year":"2010","unstructured":"Iwanaga M, Watanabe T, Utsunomiya A, Okayama A, Uchimaru K, Koh KR, et al. Human T-cell leukemia virus type I (HTLV-1) proviral load and disease progression in asymptomatic HTLV-1 carriers: a nationwide prospective study in Japan. Blood. 2010;116:1211\u20139.","journal-title":"Blood"},{"issue":"1","key":"4156_CR74","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s40364-025-00747-5","volume":"13","author":"K Jimbo","year":"2025","unstructured":"Jimbo K, Nojima M, Toriuchi K, Yamagishi M, Nakashima M, Yamano Y, et al. Long-term kinetics of proviral load in HTLV-1 carriers: defining risk for the development of adult T-cell leukemia\/lymphoma. Biomark Res. 2025;13(1):34. https:\/\/doi.org\/10.1186\/s40364-025-00747-5.","journal-title":"Biomark Res"},{"issue":"1","key":"4156_CR75","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1038\/s42003-022-04284-x","volume":"5","author":"T Kameda","year":"2022","unstructured":"Kameda T, Shide K, Kamiunten A, Kogure Y, Morishita D, Koya J, et al. CARD11 mutation and HBZ expression induce lymphoproliferative disease and adult T-cell leukemia\/lymphoma. Commun Biol. 2022;5(1):1309. https:\/\/doi.org\/10.1038\/s42003-022-04284-x.","journal-title":"Commun Biol"},{"key":"4156_CR76","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.ccr.2011.12.015","volume":"21","author":"M Yamagishi","year":"2012","unstructured":"Yamagishi M, Nakano K, Miyake A, Yamochi T, Kagami Y, Tsutsumi A, et al. Polycomb-mediated loss of miR-31 activates NIK-dependent NF-\u03baB pathway in adult T cell leukemia and other cancers. Cancer Cell. 2012;21:121\u201335.","journal-title":"Cancer Cell"},{"key":"4156_CR77","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1182\/blood-2015-08-662593","volume":"127","author":"D Fujikawa","year":"2016","unstructured":"Fujikawa D, Nakagawa S, Hori M, Kurokawa N, Soejima A, Nakano K, et al. Polycomb-dependent epigenetic landscape in adult T-cell leukemia. Blood. 2016;127:1790\u2013802.","journal-title":"Blood"},{"issue":"8","key":"4156_CR78","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.1016\/j.celrep.2019.10.083","volume":"29","author":"M Yamagishi","year":"2019","unstructured":"Yamagishi M, Hori M, Fujikawa D, Ohsugi T, Honma D, Adachi N, et al. Targeting excessive EZH1 and EZH2 activities for abnormal histone methylation and transcription network in malignant lymphomas. Cell Rep. 2019;29(8):2321-2337.e7. https:\/\/doi.org\/10.1016\/j.celrep.2019.10.083.","journal-title":"Cell Rep"},{"issue":"8002","key":"4156_CR79","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1038\/s41586-024-07103-x","volume":"627","author":"M Yamagishi","year":"2024","unstructured":"Yamagishi M, Kuze Y, Kobayashi S, Nakashima M, Morishima S, Kawamata T, et al. Mechanisms of action and resistance in histone methylation-targeted therapy. Nature. 2024;627(8002):221\u20138. https:\/\/doi.org\/10.1038\/s41586-024-07103-x.","journal-title":"Nature"},{"key":"4156_CR80","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1111\/cas.16388","volume":"116","author":"J Mizuike","year":"2025","unstructured":"Mizuike J, Suzuki K, Tosaka S, Kuze Y, Kobayashi S, Nakashima M, et al. Rewired chromatin structure and epigenetic gene dysregulation during HTLV-1 infection to leukemogenesis. Cancer Sci. 2025;116:513\u201323. https:\/\/doi.org\/10.1111\/cas.16388.","journal-title":"Cancer Sci"},{"key":"4156_CR81","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1182\/blood.2019003084","volume":"136","author":"T Watanabe","year":"2020","unstructured":"Watanabe T, Yamashita S, Ureshino H, Kamachi K, Kurahashi Y, Fukuda-Kurahashi Y, et al. Targeting aberrant DNA hypermethylation as a driver of ATL leukemogenesis by using the new oral demethylating agent OR-2100. Blood. 2020;136:871\u201384.","journal-title":"Blood"},{"issue":"10","key":"4156_CR82","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1038\/s41375-025-02725-0","volume":"39","author":"K Suzuki","year":"2025","unstructured":"Suzuki K, Kusayanagi S, Kuze Y, Hata M, Kozuma S, Jimbo K, et al. Bidirectional anti-tumor and immunological strategies by targeting GARP-TGF-\u03b2 axis in adult T-cell leukemia\/lymphoma. Leukemia. 2025;39(10):2465\u201376. https:\/\/doi.org\/10.1038\/s41375-025-02725-0.","journal-title":"Leukemia"},{"key":"4156_CR83","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/S0140-6736(64)91524-7","volume":"1","author":"MA Epstein","year":"1964","unstructured":"Epstein MA, Achong BG, Barr YM. Virus particles in cultured lymphoblasts from Burkitt\u2019s lymphoma. Lancet. 1964;1:702\u20133.","journal-title":"Lancet"},{"key":"4156_CR84","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1038\/s41579-019-0249-7","volume":"17","author":"C M\u00fcnz","year":"2019","unstructured":"M\u00fcnz C. Latency and lytic replication in Epstein-Barr virus-associated oncogenesis. Nat Rev Microbiol. 2019;17:691\u2013700.","journal-title":"Nat Rev Microbiol"},{"issue":"1","key":"4156_CR85","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1200\/JCO.2016.68.1619","volume":"35","author":"M Yamaguchi","year":"2017","unstructured":"Yamaguchi M, Suzuki R, Oguchi M, Asano N, Amaki J, Akiba T, et al. Treatments and outcomes of patients with extranodal natural killer\/T-cell lymphoma diagnosed between 2000 and 2013: a cooperative study in Japan. J Clin Oncol. 2017;35(1):32\u20139. https:\/\/doi.org\/10.1200\/JCO.2016.68.1619.","journal-title":"J Clin Oncol"},{"issue":"4","key":"4156_CR86","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1038\/s41375-025-02527-4","volume":"39","author":"A Fujimoto","year":"2025","unstructured":"Fujimoto A, Miyazaki K, Yakushijin K, Fujino T, Munakata W, Ejima Y, et al. Improved prognosis of advanced-stage extranodal NK\/T-cell lymphoma: results of the NKEA-Next study. Leukemia. 2025;39(4):909\u201316. https:\/\/doi.org\/10.1038\/s41375-025-02527-4.","journal-title":"Leukemia"},{"issue":"5","key":"4156_CR87","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1007\/s12185-023-03660-5","volume":"118","author":"JI Kawada","year":"2023","unstructured":"Kawada JI, Ito Y, Ohshima K, Yamada M, Kataoka S, Muramatsu H, et al. Updated guidelines for chronic active Epstein-Barr virus disease. Int J Hematol. 2023;118(5):568\u201376. https:\/\/doi.org\/10.1007\/s12185-023-03660-5.","journal-title":"Int J Hematol"},{"issue":"13","key":"4156_CR88","doi-asserted-by":"publisher","first-page":"2918","DOI":"10.1182\/bloodadvances.2020001451","volume":"4","author":"I Yonese","year":"2020","unstructured":"Yonese I, Sakashita C, Imadome KI, Kobayashi T, Yamamoto M, Sawada A, et al. Nationwide survey of systemic chronic active EBV infection in Japan in accordance with the new WHO classification. Blood Adv. 2020;4(13):2918\u201326. https:\/\/doi.org\/10.1182\/bloodadvances.2020001451.","journal-title":"Blood Adv"},{"issue":"6","key":"4156_CR89","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1002\/ajh.26544","volume":"97","author":"M Yamamoto","year":"2022","unstructured":"Yamamoto M, Sato M, Onishi Y, Sasahara Y, Sano H, Masuko M, et al. Registry data analysis of hematopoietic stem cell transplantation on systemic chronic active Epstein-Barr virus infection patients in Japan. Am J Hematol. 2022;97(6):780\u201390. https:\/\/doi.org\/10.1002\/ajh.26544.","journal-title":"Am J Hematol"},{"issue":"10","key":"4156_CR90","doi-asserted-by":"publisher","first-page":"7900","DOI":"10.1128\/JVI.72.10.7900-7908.1998","volume":"72","author":"O Devergne","year":"1998","unstructured":"Devergne O, McFarland EC, Mosialos G, Izumi KM, Ware CF, Kieff E. Role of the TRAF binding site and NF-kappaB activation in Epstein\u2013Barr virus latent membrane protein 1-induced cell gene expression. J Virol. 1998;72(10):7900\u20138.","journal-title":"J Virol"},{"issue":"26","key":"4156_CR91","doi-asserted-by":"publisher","first-page":"15595","DOI":"10.1073\/pnas.2136756100","volume":"100","author":"M Luftig","year":"2003","unstructured":"Luftig M, Prinarakis E, Yasui T, Tsichritzis T, Cahir-McFarland E, Inoue J, et al. Epstein-Barr virus latent membrane protein 1 activation of NF-kappaB through IRAK1 and TRAF6. Proc Natl Acad Sci USA. 2003;100(26):15595\u2013600. https:\/\/doi.org\/10.1073\/pnas.2136756100.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"4156_CR92","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1073\/pnas.2237183100","volume":"101","author":"M Luftig","year":"2004","unstructured":"Luftig M, Yasui T, Soni V, Kang MS, Jacobson N, Cahir-McFarland E, et al. Epstein-Barr virus latent infection membrane protein 1 TRAF-binding site induces NIK\/IKK alpha-dependent noncanonical NF-kappaB activation. Proc Natl Acad Sci USA. 2004;101(1):141\u20136. https:\/\/doi.org\/10.1073\/pnas.2237183100.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"4156_CR93","doi-asserted-by":"publisher","first-page":"3694","DOI":"10.1074\/jbc.M209840200","volume":"278","author":"CW Dawson","year":"2003","unstructured":"Dawson CW, Tramountanis G, Eliopoulos AG, Young LS. Epstein-Barr virus latent membrane protein 1 (LMP1) activates the phosphatidylinositol 3-kinase\/Akt pathway to promote cell survival and induce actin filament remodeling. J Biol Chem. 2003;278(6):3694\u2013704.","journal-title":"J Biol Chem"},{"issue":"12","key":"4156_CR94","doi-asserted-by":"publisher","first-page":"8225","DOI":"10.4049\/jimmunol.179.12.8225","volume":"179","author":"SL Lambert","year":"2007","unstructured":"Lambert SL, Martinez OM. Latent membrane protein 1 of EBV activates phosphatidylinositol 3-kinase to induce production of IL 10. J Immunol. 2007;179(12):8225\u201334.","journal-title":"J Immunol"},{"key":"4156_CR95","doi-asserted-by":"publisher","first-page":"5412","DOI":"10.1158\/1078-0432.CCR-13-3172","volume":"20","author":"J Kawada","year":"2014","unstructured":"Kawada J, Ito Y, Iwata S, Suzuki M, Kawano Y, Kanazawa T, et al. mTOR inhibitors induce cell-cycle arrest and inhibit tumor growth in Epstein\u2013Barr virus-associated T and natural killer cell lymphoma cells. Clin Cancer Res. 2014;20:5412\u201322.","journal-title":"Clin Cancer Res"},{"issue":"11","key":"4156_CR96","doi-asserted-by":"publisher","first-page":"3064","DOI":"10.1093\/emboj\/18.11.3064","volume":"18","author":"O Gires","year":"1999","unstructured":"Gires O, Kohlhuber F, Kilger E, Baumann M, Kieser A, Kaiser C, et al. Latent membrane protein 1 of Epstein-Barr virus interacts with JAK3 and activates STAT proteins. EMBO J. 1999;18(11):3064\u201373.","journal-title":"EMBO J"},{"issue":"1","key":"4156_CR97","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1128\/JVI.76.1.455-459.2002","volume":"76","author":"M Higuchi","year":"2002","unstructured":"Higuchi M, Kieff E, Izumi KM. The Epstein-Barr virus latent membrane protein 1 putative Janus kinase 3 (JAK3) binding domain does not mediate Jak3 association or activation in B lymphoma or lymphoblastoid cell lines. J Virol. 2002;76(1):455\u20139.","journal-title":"J Virol"},{"issue":"47","key":"4156_CR98","doi-asserted-by":"publisher","first-page":"76793","DOI":"10.18632\/oncotarget.12529","volume":"7","author":"S Ando","year":"2016","unstructured":"Ando S, Kawada JI, Watanabe T, Suzuki M, Sato Y, Torii Y, et al. Tofacitinib induces G1 cell-cycle arrest and inhibits tumor growth in Epstein-Barr virus-associated T and natural killer cell lymphoma cells. Oncotarget. 2016;7(47):76793\u2013805.","journal-title":"Oncotarget"},{"issue":"57","key":"4156_CR99","doi-asserted-by":"publisher","first-page":"31077","DOI":"10.18632\/oncotarget.25780","volume":"9","author":"E Onozawa","year":"2018","unstructured":"Onozawa E, Shibayama H, Takada H, Imadome KI, Aoki S, Yoshimori M, et al. STAT3 is constitutively activated in chronic active Epstein-Barr virus infection and can be a therapeutic target. Oncotarget. 2018;9(57):31077\u201389.","journal-title":"Oncotarget"},{"issue":"3","key":"4156_CR100","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0174136","volume":"12","author":"H Takada","year":"2017","unstructured":"Takada H, Imadome KI, Shibayama H, Yoshimori M, Wang L, Saitoh Y, et al. EBV induces persistent NF-\u03baB activation and contributes to survival of EBV-positive neoplastic T- or NK-cells. PLoS ONE. 2017;12(3):e0174136. https:\/\/doi.org\/10.1371\/journal.pone.0174136.","journal-title":"PLoS ONE"},{"issue":"5","key":"4156_CR101","doi-asserted-by":"publisher","first-page":"2253","DOI":"10.3892\/or.2015.3847","volume":"33","author":"L Sun","year":"2015","unstructured":"Sun L, Zhao Y, Shi H, Ma C, Wei L. LMP-1 induces survivin expression to inhibit cell apoptosis through the NF-\u03baB and PI3K\/Akt signaling pathways in nasal NK\/T-cell lymphoma. Oncol Rep. 2015;33(5):2253\u201360.","journal-title":"Oncol Rep"},{"issue":"9","key":"4156_CR102","doi-asserted-by":"publisher","first-page":"4399","DOI":"10.1128\/JVI.01703-10","volume":"85","author":"CP Kung","year":"2011","unstructured":"Kung CP, Meckes DG Jr, Raab-Traub N. Epstein-Barr virus LMP1 activates EGFR, STAT3, and ERK through effects on PKCdelta. J Virol. 2011;85(9):4399\u2013408.","journal-title":"J Virol"},{"issue":"11","key":"4156_CR103","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0112564","volume":"9","author":"M Yoshimori","year":"2014","unstructured":"Yoshimori M, Imadome K, Komatsu H, Wang L, Saitoh Y, Yamaoka S. CD137 expression is induced by Epstein-Barr virus infection through LMP1 in T or NK cells and mediates survival promoting signals. PLoS ONE. 2014;9(11):e112564. https:\/\/doi.org\/10.1371\/journal.pone.0112564.","journal-title":"PLoS ONE"},{"key":"4156_CR104","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.semcancer.2008.10.004","volume":"18","author":"JM Middeldorp","year":"2008","unstructured":"Middeldorp JM, Pegtel DM. Multiple roles of LMP1 in Epstein\u2013Barr virus induced immune escape. Semin Cancer Biol. 2008;18:388\u201396.","journal-title":"Semin Cancer Biol"},{"key":"4156_CR105","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1097\/PAS.0000000000001919","volume":"46","author":"A Kume","year":"2022","unstructured":"Kume A, Shinozaki-Ushiku A, Kunita A, Kondo A, Ushiku T. Enhanced PD-L1 expression in LMP1-positive cells of Epstein-Barr virus-associated malignant lymphomas and lymphoproliferative disorders: a single-cell resolution analysis with multiplex fluorescence immunohistochemistry and in situ hybridization. Am J Surg Pathol. 2022;46:1386\u201396.","journal-title":"Am J Surg Pathol"},{"key":"4156_CR106","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s13045-016-0341-7","volume":"9","author":"XW Bi","year":"2016","unstructured":"Bi XW, Wang H, Zhang WW, Wang JH, Liu WJ, Xia ZJ, et al. PD-L1 is upregulated by EBV-driven LMP1 through NF-kappaB pathway and correlates with poor prognosis in natural killer\/T-cell lymphoma. J Hematol Oncol. 2016;9:109.","journal-title":"J Hematol Oncol"},{"key":"4156_CR107","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1038\/s41375-024-02266-y","volume":"38","author":"Y Li","year":"2024","unstructured":"Li Y, Chen K, Chen B, Zeng R, He Y, Wang C, et al. Increased coexpression of PD-L1 and IDO1 is associated with poor overall survival in patients with NK\/T-cell lymphoma. Leukemia. 2024;38:1553\u201363.","journal-title":"Leukemia"},{"issue":"23","key":"4156_CR108","doi-asserted-by":"publisher","first-page":"2552","DOI":"10.1182\/blood-2017-07-794529","volume":"131","author":"H Higuchi","year":"2018","unstructured":"Higuchi H, Yamakawa N, Imadome KI, Yahata T, Kotaki R, Ogata J, et al. Role of exosomes as a proinflammatory mediator in the development of EBV-associated lymphoma. Blood. 2018;131(23):2552\u201367.","journal-title":"Blood"},{"issue":"3","key":"4156_CR109","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1038\/s41564-018-0334-0","volume":"4","author":"Y Okuno","year":"2019","unstructured":"Okuno Y, Murata T, Sato Y, Muramatsu H, Ito Y, Watanabe T, et al. Defective Epstein-Barr virus in chronic active infection and haematological malignancy. Nat Microbiol. 2019;4(3):404\u201313. https:\/\/doi.org\/10.1038\/s41564-018-0334-0.","journal-title":"Nat Microbiol"},{"issue":"12","key":"4156_CR110","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.00394-22","volume":"96","author":"W Wongwiwat","year":"2022","unstructured":"Wongwiwat W, Fournier B, Bassano I, Bayoumy A, Elgueta Karstegl C, Styles C, et al. Epstein-barr virus genome deletions in epstein-barr virus-positive T\/NK cell lymphoproliferative diseases. J Virol. 2022;96(12):e0039422.","journal-title":"J Virol"},{"issue":"2","key":"4156_CR111","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1111\/bjh.17790","volume":"195","author":"C Venturini","year":"2021","unstructured":"Venturini C, Houldcroft CJ, Lazareva A, Wegner F, Morfopoulou S, Amrolia PJ, et al. Epstein-Barr virus (EBV) deletions as biomarkers of response to treatment of chronic active EBV. Br J Haematol. 2021;195(2):249\u201355.","journal-title":"Br J Haematol"},{"key":"4156_CR112","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-025-04040-x","author":"M Yoshimori","year":"2025","unstructured":"Yoshimori M, Nishio M, Ohashi A, Maekawa Y, Shimomaki R, Kurata M, et al. Expression profiling of Epstein-Barr virus-derived microRNA in systemic chronic active EBV disease. Int J Hematol. 2025. https:\/\/doi.org\/10.1007\/s12185-025-04040-x.","journal-title":"Int J Hematol"},{"key":"4156_CR113","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1038\/ng.3358","volume":"47","author":"L Jiang","year":"2015","unstructured":"Jiang L, Gu ZH, Yan ZX, Zhao X, Xie YY, Zhang ZG, et al. Exome sequencing identi es somatic mutations of DDX3X in natural killer\/T-cell lymphoma. Nat Genet. 2015;47:1061\u20136.","journal-title":"Nat Genet"},{"issue":"13","key":"4156_CR114","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1158\/0008-5472.CAN-24-0132","volume":"84","author":"Y Ito","year":"2024","unstructured":"Ito Y, Marouf A, Kogure Y, Koya J, Li\u00e9vin R, Bruneau J, et al. Comprehensive genetic profiling reveals frequent alterations of driver genes on the X chromosome in extranodal NK\/T-cell lymphoma. Cancer Res. 2024;84(13):2181\u2013201.","journal-title":"Cancer Res"},{"issue":"1","key":"4156_CR115","doi-asserted-by":"publisher","first-page":"9106","DOI":"10.1038\/s41467-024-53376-1","volume":"15","author":"J Koya","year":"2024","unstructured":"Koya J, Tanigawa T, Mizuno K, Kim H, Ito Y, Yuasa M, et al. Modeling NK-cell lymphoma in mice reveals its cell-of-origin and microenvironmental changes and identifies therapeutic targets. Nat Commun. 2024;15(1):9106. https:\/\/doi.org\/10.1038\/s41467-024-53376-1.","journal-title":"Nat Commun"},{"key":"4156_CR116","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1038\/s41375-019-0380-5","volume":"33","author":"K Kataoka","year":"2019","unstructured":"Kataoka K, Miyoshi H, Sakata S, Dobashi A, Couronn\u00e9 L, Kogure Y, et al. Frequent structural variations involving programmed death ligands in Epstein-Barr virus-associated lymphomas. Leukemia. 2019;33:1687\u201399.","journal-title":"Leukemia"},{"issue":"3","key":"4156_CR117","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.ccell.2020.02.005","volume":"37","author":"J Xiong","year":"2020","unstructured":"Xiong J, Cui BW, Wang N, Dai YT, Zhang H, Wang CF, et al. Genomic and transcriptomic characterization of natural killer T cell lymphoma. Cancer Cell. 2020;37(3):403-419.e6. https:\/\/doi.org\/10.1016\/j.ccell.2020.02.005.","journal-title":"Cancer Cell"},{"issue":"4","key":"4156_CR118","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1016\/j.jaci.2022.11.012","volume":"151","author":"H Luo","year":"2023","unstructured":"Luo H, Liu D, Liu W, Jin J, Bi X, Zhang P, et al. Clinical and genetic characterization of Epstein-Barr virus-associated T\/NK-cell lymphoproliferative diseases. J Allergy Clin Immunol. 2023;151(4):1096\u2013109.","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"4156_CR119","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1158\/2643-3230.BCD-21-0098","volume":"3","author":"BL Mundy-Bosse","year":"2022","unstructured":"Mundy-Bosse BL, Weigel C, Wu YZ, Abdelbaky S, Youssef Y, Casas SB, et al. Identification and targeting of the developmental blockade in extranodal natural killer\/T-cell lymphoma. Blood Cancer Discov. 2022;3(2):154\u201369. https:\/\/doi.org\/10.1158\/2643-3230.BCD-21-0098.","journal-title":"Blood Cancer Discov"},{"issue":"19","key":"4156_CR120","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1182\/blood.2024026805","volume":"146","author":"R Akazawa","year":"2025","unstructured":"Akazawa R, Mikami T, Yamada M, Kato I, Kubota H, Saida S, et al. Multiomics analysis reveals the genetic and epigenetic features of high-risk NK cell-type chronic active EBV infection. Blood. 2025;146(19):2336\u201349. https:\/\/doi.org\/10.1182\/blood.2024026805.","journal-title":"Blood"},{"issue":"10","key":"4156_CR121","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1038\/s41579-025-01181-y","volume":"23","author":"C M\u00fcnz","year":"2025","unstructured":"M\u00fcnz C. Epstein-Barr virus pathogenesis and emerging control strategies. Nat Rev Microbiol. 2025;23(10):667\u201379.","journal-title":"Nat Rev Microbiol"},{"issue":"24","key":"4156_CR122","doi-asserted-by":"publisher","first-page":"2754","DOI":"10.1182\/blood.2020007247","volume":"136","author":"SJ Kim","year":"2020","unstructured":"Kim SJ, Lim JQ, Laurensia Y, Cho J, Yoon SE, Lee JY, et al. Avelumab for the treatment of relapsed or refractory extranodal NK\/T-cell lymphoma: an open-label phase 2 study. Blood. 2020;136(24):2754\u201363. https:\/\/doi.org\/10.1182\/blood.2020007247.","journal-title":"Blood"},{"key":"4156_CR123","unstructured":"Makita S, Koya J, Suzuki Y, Nishikori M, Fukuhara N, Maeshima AM, et al. Phase 2 study of anti-PD-L1 antibody atezolizumab in patients with relapsed\/refractory extranodal natural killer\/T-cell lymphoma: NCCH1903\/ATTACK study. European Hematology Association 2024 (Abstract: P1170)."},{"key":"4156_CR124","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1182\/bloodadvances.2020002417","volume":"5","author":"M Yoshimori","year":"2021","unstructured":"Yoshimori M, Shibayama H, Imadome KI, Kawano F, Ohashi A, Nishio M, et al. Antineoplastic and anti-inflammatory effects of bortezomib on systemic chronic active EBV infection. Blood Adv. 2021;5:1805\u201315. https:\/\/doi.org\/10.1182\/bloodadvances.2020002417.","journal-title":"Blood Adv"},{"issue":"1","key":"4156_CR125","doi-asserted-by":"publisher","DOI":"10.1016\/j.bneo.2024.100053","volume":"2","author":"Y Uemura","year":"2024","unstructured":"Uemura Y, Yamamoto M, Ishimura M, Kanegane H, Sawada A, Hirakawa A, et al. JAK1\/2 inhibitor ruxolitinib for the treatment of systemic chronic active Epstein-Barr virus disease: a phase 2 study. Blood Neoplasia. 2024;2(1):100053. https:\/\/doi.org\/10.1016\/j.bneo.2024.100053.","journal-title":"Blood Neoplasia"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-025-04156-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-025-04156-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-025-04156-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T13:02:06Z","timestamp":1776258126000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-025-04156-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,7]]},"references-count":125,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["4156"],"URL":"https:\/\/doi.org\/10.1007\/s12185-025-04156-0","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,7]]},"assertion":[{"value":"18 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 December 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The author declares that there is no conflict of interest to be disclosed.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}